COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

30,962 Articles (22,604 medRxiv, 8,358 bioRxiv)

Most recent first Previous |  Page 2: Articles 11-20  | Next

ISG15 Differentially Modulates Clade Ib and II MPXV Infection in MEF cells
McGrail, J. P., Campana Gomez, I., Tuhkala, A., Keskitalo, S. E., Varjosalo, M., Garcia-Sastre, A., Palacios, G. F., Sanchez-Seco, M. P., Guerra, S.
10.1101/2025.09.26.678780 — Posted: 2025-09-26
A Comparative Nanomechanical Study of Antibody and Nanobody Binding to SARS-CoV-2 Variants
Cofas-Vargas, L. F., Olivos-Ramirez, G. E., Marrink, S.-J., Poma, A. B.
10.1101/2025.09.26.672567 — Posted: 2025-09-26
Late treatment initiation leads to reduced antiviral potency
Liu, X., Franco, E. J., Avedissian, S. N., Hanrahan, K. C., Guedj, J., van Hasselt, J. G. C., Brown, A. N., Martson, A.-G.
10.1101/2025.09.24.678199 — Posted: 2025-09-25
SARS-CoV-2 ORF7a Drives Mitochondrial Dysfunction via PDK4 Activation and Complex I Inhibition
Fernandez-Rodriguez, R., Soto-Jimenez, C. M., Acin-Perez, R., de Lucas-Rius, A., Sanchez-Mendoza, L. M., Lopez-Ayllon, B. D., Villalba, J. M., Enriquez, J. A., Montoya, M., Garrido, J. J., Garcia-Garcia, T.
10.1101/2025.09.25.678549 — Posted: 2025-09-25
How many crystal structures do you need to trust your docking results?
Payne, A. M., Kaminow, B., MacDermott-Opeskin, H., Pulido, I., Scheen, J., Castellanos, M. A., Fearon, D., Chodera, J. D., Singh, S.
10.1101/2025.09.19.677428 — Posted: 2025-09-24
VSA-2, a novel plant-derived adjuvant for SARS-CoV-2 subunit vaccine
Adam, A., Lee, C., Jones, M. C., Harrington, B. R., Zou, J., Peng, B.-H., Xie, X., Wang, P., Wang, T.
10.1101/2025.09.22.677856 — Posted: 2025-09-24
A Novel dual Influenza virus and SARS-CoV-2 neutralisation assay
da Costa, K. A. S., Mayora-Neto, M., Adigun, S. F., Shobande, T. T., Amoaka-Tawiah, D., Masud, S., Basaru-Sanni, T. O., Coopoomootoo, P., Jones, A. W., Davison, G., Pjechova, M., Miller, A. D., Fajfr, M., Ruzek, D., Temperton, N. J.
10.1101/2025.09.19.677384 — Posted: 2025-09-23
Redirection of SARS-CoV-2 to phagocytes by intranasal sACE2-Fc as a universal decoy confers complete prophylactic protection
Wang, J., Li, J., Chin, A. W., Luo, B., Wei, J., Qiu, J., Ren, J., Xia, Y., Braun, T., L M Poon, L. L. M., Feng, B.
10.1101/2025.09.23.677998 — Posted: 2025-09-23
High-throughput cell-free profiling of SARS-CoV-2 RBD variants enables rapid and quantitative in vitro affinity landscape mapping
Grasemann, L., Han, J., Tischler, J., Arefi, F., Castillo, M. A. G., Irvine, E. B., Chen, N., Reddy, S. T., Maerkl, S. J.
10.1101/2025.09.23.678000 — Posted: 2025-09-23
PRIME: A Multi-Agent Environment for Orchestrating Dynamic Computational Workflows in Protein Engineering
Zhou, Y., Su, J., Zhang, J., Hu, W., Tao, T., Li, G., Zhou, X., Fan, L., Yuan, F.
10.1101/2025.09.22.677756 — Posted: 2025-09-23

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).